[
  {
    "ts": null,
    "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
    "summary": "Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?",
    "url": "https://finnhub.io/api/news?id=90461fe2b10ef9c117a39ff656e5a36792ceef896cca2c913a981ad8f3b24764",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768855440,
      "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
      "id": 138180931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?",
      "url": "https://finnhub.io/api/news?id=90461fe2b10ef9c117a39ff656e5a36792ceef896cca2c913a981ad8f3b24764"
    }
  },
  {
    "ts": null,
    "headline": "The Magnificent 7 is Over: What Stocks Will Replace It?",
    "summary": "Amazon and Tesla have underperformed for 5 years. Is it time to give them the boot?",
    "url": "https://finnhub.io/api/news?id=54542035994c9839321ff638ca9b35e8587e7bececf7a374096e9a80ffeec368",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768839240,
      "headline": "The Magnificent 7 is Over: What Stocks Will Replace It?",
      "id": 138178948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amazon and Tesla have underperformed for 5 years. Is it time to give them the boot?",
      "url": "https://finnhub.io/api/news?id=54542035994c9839321ff638ca9b35e8587e7bececf7a374096e9a80ffeec368"
    }
  },
  {
    "ts": null,
    "headline": "The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever",
    "summary": "All three of these healthcare giants are leaders in their niches.",
    "url": "https://finnhub.io/api/news?id=e9939cfef0c4f38db1d0b06d2ca2ed24229091e544d012753c94937eb114cc79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768838820,
      "headline": "The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever",
      "id": 138178998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "All three of these healthcare giants are leaders in their niches.",
      "url": "https://finnhub.io/api/news?id=e9939cfef0c4f38db1d0b06d2ca2ed24229091e544d012753c94937eb114cc79"
    }
  },
  {
    "ts": null,
    "headline": "Transformative arrival of oral weight loss medicines in the US",
    "summary": "While GlobalData does not expect oral Wegovy to substantially displace sales of injectable versions in 2026, some sales cannibalisation in the medium-term outlook is inevitable.",
    "url": "https://finnhub.io/api/news?id=d014e44bbb884726c8b63d1eb0c2d2246331afe3440c307eecbe37c26e190256",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768837081,
      "headline": "Transformative arrival of oral weight loss medicines in the US",
      "id": 138177942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While GlobalData does not expect oral Wegovy to substantially displace sales of injectable versions in 2026, some sales cannibalisation in the medium-term outlook is inevitable.",
      "url": "https://finnhub.io/api/news?id=d014e44bbb884726c8b63d1eb0c2d2246331afe3440c307eecbe37c26e190256"
    }
  },
  {
    "ts": null,
    "headline": "Compounder sues Lilly and Novo for suppressing GLP-1RA competition",
    "summary": "Strive Compounding Pharmacy alleges the two pharma companies are coordinating an effort to restrict compounded access.",
    "url": "https://finnhub.io/api/news?id=45be34343983be188be84e337c04ad7ca0993c5b306e87d7c8f8e6e9803c3b9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768836249,
      "headline": "Compounder sues Lilly and Novo for suppressing GLP-1RA competition",
      "id": 138177943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Strive Compounding Pharmacy alleges the two pharma companies are coordinating an effort to restrict compounded access.",
      "url": "https://finnhub.io/api/news?id=45be34343983be188be84e337c04ad7ca0993c5b306e87d7c8f8e6e9803c3b9b"
    }
  },
  {
    "ts": null,
    "headline": "Podcast: JPM26’s dealmaking falls short of expectations",
    "summary": "Despite lacklustre dealmaking, there were still trends identified from company presentations, such as pharma's upcoming patent cliff and AI's growth in medtech.",
    "url": "https://finnhub.io/api/news?id=79ac97520c3274b9c75d4113b3e9dca11d4885c2ca6fe43e18bef3f770d0db2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768835425,
      "headline": "Podcast: JPM26’s dealmaking falls short of expectations",
      "id": 138177901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Despite lacklustre dealmaking, there were still trends identified from company presentations, such as pharma's upcoming patent cliff and AI's growth in medtech.",
      "url": "https://finnhub.io/api/news?id=79ac97520c3274b9c75d4113b3e9dca11d4885c2ca6fe43e18bef3f770d0db2d"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already?",
    "summary": "NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch.",
    "url": "https://finnhub.io/api/news?id=cb05e9b64c2674e2022ec89010d83e41c893466d5f60a9cff2c6bdaf602e0589",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768834740,
      "headline": "Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already?",
      "id": 138178524,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch.",
      "url": "https://finnhub.io/api/news?id=cb05e9b64c2674e2022ec89010d83e41c893466d5f60a9cff2c6bdaf602e0589"
    }
  },
  {
    "ts": null,
    "headline": "Huge Insider Buying Now at This Insurance Giant and 2 Biotechs",
    "summary": "Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.",
    "url": "https://finnhub.io/api/news?id=6141ffe3739b398eb464d103e6cbbba206beb156e03b900fd0a3393cfe67771d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768830346,
      "headline": "Huge Insider Buying Now at This Insurance Giant and 2 Biotechs",
      "id": 138177945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.",
      "url": "https://finnhub.io/api/news?id=6141ffe3739b398eb464d103e6cbbba206beb156e03b900fd0a3393cfe67771d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial. This study is the first controlled pharmacologic trial to evaluate the combined use of an incretin therapy, Zepbound (tirzepatide), alongside a […]",
    "url": "https://finnhub.io/api/news?id=b76af655b8d95efcb25dd247fb0d79307b565eb12f34f6db342215e6b76d97b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768827003,
      "headline": "Eli Lilly’s Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial",
      "id": 138176991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial. This study is the first controlled pharmacologic trial to evaluate the combined use of an incretin therapy, Zepbound (tirzepatide), alongside a […]",
      "url": "https://finnhub.io/api/news?id=b76af655b8d95efcb25dd247fb0d79307b565eb12f34f6db342215e6b76d97b6"
    }
  },
  {
    "ts": null,
    "headline": "Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan",
    "summary": "Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.",
    "url": "https://finnhub.io/api/news?id=503f4b6fbb9bb2db559370a3732a67ffc25763a4cff27963a2a84b662fa84d15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768826280,
      "headline": "Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan",
      "id": 138177946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.",
      "url": "https://finnhub.io/api/news?id=503f4b6fbb9bb2db559370a3732a67ffc25763a4cff27963a2a84b662fa84d15"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: 2026 Will Be the Year of Eli Lilly",
    "summary": "A catalyst lies just ahead.",
    "url": "https://finnhub.io/api/news?id=7798a36634e162a1340675188feadd8cc0dde9be2c857bf04dde075c1d69ce5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768815000,
      "headline": "Prediction: 2026 Will Be the Year of Eli Lilly",
      "id": 138175732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A catalyst lies just ahead.",
      "url": "https://finnhub.io/api/news?id=7798a36634e162a1340675188feadd8cc0dde9be2c857bf04dde075c1d69ce5b"
    }
  },
  {
    "ts": null,
    "headline": "Where is NVIDIA Corporation (NVDA) Headed According to the Street?",
    "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the best strong buy growth stocks to buy according to hedge funds. NVIDIA Corporation (NASDAQ:NVDA) received a rating update from Jefferies on January 16, with the firm lifting the price target on the stock to $275 from $250 and maintaining a Buy rating on the shares. The firm told […]",
    "url": "https://finnhub.io/api/news?id=73fcde780a050f087cb6e08e8f4ac2f558f461c218de6e3f4a7ef3e113615430",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768814355,
      "headline": "Where is NVIDIA Corporation (NVDA) Headed According to the Street?",
      "id": 138175719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the best strong buy growth stocks to buy according to hedge funds. NVIDIA Corporation (NASDAQ:NVDA) received a rating update from Jefferies on January 16, with the firm lifting the price target on the stock to $275 from $250 and maintaining a Buy rating on the shares. The firm told […]",
      "url": "https://finnhub.io/api/news?id=73fcde780a050f087cb6e08e8f4ac2f558f461c218de6e3f4a7ef3e113615430"
    }
  },
  {
    "ts": null,
    "headline": "What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative",
    "summary": "In recent weeks, Eli Lilly has deepened its push into AI-driven drug discovery and obesity care, including a planned US$1.00 billion co-innovation lab with NVIDIA, new AI collaborations such as Chai Discovery and TuneLab integrations, and positive Phase 3b data combining Taltz with Zepbound in psoriatic arthritis and obesity. At the same time, Strive Compounding Pharmacy’s federal antitrust lawsuit against Eli Lilly and Novo Nordisk over compounded GLP-1 access underscores growing legal and...",
    "url": "https://finnhub.io/api/news?id=1d40f2717d59d59da33f6602aa437713e604dd40bdceabf2cb0941e0b7dcd1ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768785039,
      "headline": "What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative",
      "id": 138173427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In recent weeks, Eli Lilly has deepened its push into AI-driven drug discovery and obesity care, including a planned US$1.00 billion co-innovation lab with NVIDIA, new AI collaborations such as Chai Discovery and TuneLab integrations, and positive Phase 3b data combining Taltz with Zepbound in psoriatic arthritis and obesity. At the same time, Strive Compounding Pharmacy’s federal antitrust lawsuit against Eli Lilly and Novo Nordisk over compounded GLP-1 access underscores growing legal and...",
      "url": "https://finnhub.io/api/news?id=1d40f2717d59d59da33f6602aa437713e604dd40bdceabf2cb0941e0b7dcd1ad"
    }
  }
]